DE602005014955D1 - Verbindungen und verfahren zur behandlung von dyslipidämie - Google Patents

Verbindungen und verfahren zur behandlung von dyslipidämie

Info

Publication number
DE602005014955D1
DE602005014955D1 DE602005014955T DE602005014955T DE602005014955D1 DE 602005014955 D1 DE602005014955 D1 DE 602005014955D1 DE 602005014955 T DE602005014955 T DE 602005014955T DE 602005014955 T DE602005014955 T DE 602005014955T DE 602005014955 D1 DE602005014955 D1 DE 602005014955D1
Authority
DE
Germany
Prior art keywords
dyslipidemia
compounds
treatment
sequelae
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005014955T
Other languages
German (de)
English (en)
Inventor
Michael Gregory Bell
Guoqing Cao
Ana Maria Escribano
Maria Carmen Fernandez
Peter Ambrose Lander
Nathan Bryan Mantlo
De La Nava Eva Maria Martin
Herranz Ana Isabel Mateo
Daniel Ray Mayhugh
Xiaodong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602005014955D1 publication Critical patent/DE602005014955D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE602005014955T 2004-03-26 2005-03-17 Verbindungen und verfahren zur behandlung von dyslipidämie Expired - Fee Related DE602005014955D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55713404P 2004-03-26 2004-03-26
US62116204P 2004-10-22 2004-10-22
PCT/US2005/009301 WO2005097806A1 (en) 2004-03-26 2005-03-17 Compounds and methods for treating dyslipidemia

Publications (1)

Publication Number Publication Date
DE602005014955D1 true DE602005014955D1 (de) 2009-07-30

Family

ID=34963426

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005014955T Expired - Fee Related DE602005014955D1 (de) 2004-03-26 2005-03-17 Verbindungen und verfahren zur behandlung von dyslipidämie
DE602005008416T Expired - Fee Related DE602005008416D1 (de) 2004-03-26 2005-03-17 Verbindungen zur behandlung von dyslipidemie

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602005008416T Expired - Fee Related DE602005008416D1 (de) 2004-03-26 2005-03-17 Verbindungen zur behandlung von dyslipidemie

Country Status (21)

Country Link
US (2) US20070208003A1 (https=)
EP (2) EP1732933B1 (https=)
JP (1) JP2007530550A (https=)
KR (1) KR20070007112A (https=)
AT (2) ATE402180T1 (https=)
AU (1) AU2005230915A1 (https=)
BR (1) BRPI0508966A (https=)
CA (1) CA2557010A1 (https=)
CY (1) CY1110398T1 (https=)
DE (2) DE602005014955D1 (https=)
DK (1) DK1732933T3 (https=)
EA (1) EA200601785A1 (https=)
EC (1) ECSP066886A (https=)
ES (2) ES2326326T3 (https=)
IL (1) IL177962A0 (https=)
MA (1) MA28550B1 (https=)
NO (1) NO20064763L (https=)
PL (1) PL1732933T3 (https=)
PT (1) PT1732933E (https=)
SI (1) SI1732933T1 (https=)
WO (2) WO2005097806A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004023100D1 (de) * 2003-10-08 2009-10-22 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
JP2007530550A (ja) * 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
EA200700119A1 (ru) 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
CN101910150B (zh) 2007-11-05 2013-09-18 诺瓦提斯公司 作为cetp抑制剂、可用于治疗疾病如高脂血症或动脉硬化的4-苄基氨基-1-羧基酰基哌啶衍生物
MX2010006063A (es) 2007-12-03 2010-07-01 Novartis Ag Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
JP2011506441A (ja) * 2007-12-12 2011-03-03 アムジエン・インコーポレーテツド グリシン輸送体−１阻害薬
WO2010110380A1 (ja) * 2009-03-27 2010-09-30 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
US8455522B2 (en) 2009-05-15 2013-06-04 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
NZ596302A (en) 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
SG176009A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
US8519134B2 (en) 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
CN102858347B (zh) * 2010-02-24 2016-11-02 瑞立普萨公司 用作胆汁酸螯合剂的聚咪唑
CN103025348B (zh) 2010-05-06 2015-09-02 阿尔法科制药有限责任公司 传递类固醇到胆甾醇酯合成组织
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
SG10201605304VA (en) 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
WO2013080999A1 (ja) 2011-11-29 2013-06-06 興和株式会社 ＮＰＣ１Ｌ１及び／又はＬＩＰＧ ｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
TR201808541T4 (tr) 2013-02-14 2018-07-23 Novartis Ag Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
KR20260015867A (ko) 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1515540A (en) 1975-12-16 1978-06-28 Labaz 4-amino-trans-decahydroquinoline derivatives
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
AU6279598A (en) * 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
US7507753B2 (en) * 2001-12-28 2009-03-24 Takeda Chemical Industries Ltd. Biaryl compound and use thereof
CN1625397A (zh) 2002-02-01 2005-06-08 辉瑞产品公司 胆固醇酯转移蛋白抑制剂的控制释放药物剂型
JP2003321472A (ja) * 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
WO2004032848A2 (en) * 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
DE602004023100D1 (de) * 2003-10-08 2009-10-22 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
TWI345568B (en) * 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии

Also Published As

Publication number Publication date
EP1732933B1 (en) 2008-07-23
PL1732933T3 (pl) 2008-12-31
ATE402180T1 (de) 2008-08-15
WO2005097805A1 (en) 2005-10-20
BRPI0508966A (pt) 2007-08-21
IL177962A0 (en) 2006-12-31
DE602005008416D1 (de) 2008-09-04
ATE433984T1 (de) 2009-07-15
US7470705B2 (en) 2008-12-30
CA2557010A1 (en) 2005-10-20
EP1735320A1 (en) 2006-12-27
AU2005230915A1 (en) 2005-10-20
US20070208003A1 (en) 2007-09-06
WO2005097806A1 (en) 2005-10-20
ES2326326T3 (es) 2009-10-07
MA28550B1 (fr) 2007-04-03
PT1732933E (pt) 2008-10-20
EP1735320B1 (en) 2009-06-17
NO20064763L (no) 2006-11-22
JP2007530550A (ja) 2007-11-01
EA200601785A1 (ru) 2007-02-27
DK1732933T3 (da) 2008-10-27
SI1732933T1 (sl) 2008-10-31
US20070173526A1 (en) 2007-07-26
EP1732933A1 (en) 2006-12-20
CY1110398T1 (el) 2015-04-29
KR20070007112A (ko) 2007-01-12
ECSP066886A (es) 2006-11-24
ES2308477T3 (es) 2008-12-01

Similar Documents

Publication Publication Date Title
DE602005014955D1 (de) Verbindungen und verfahren zur behandlung von dyslipidämie
ATE528304T1 (de) Verbindungen und verfahren zur behandlung von dyslipidämie
SE0202133D0 (sv) Novel compounds
ATE433447T1 (de) Pyrimiidinverbindungen
TW200510317A (en) Caspase inhibitors and uses thereof
DK1836201T4 (da) Pyrrolidininhibitorer af IAP.
TW200617009A (en) Organic compounds
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
DE602005012811D1 (de) Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd
SE0303541D0 (sv) New compounds
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
TW200510427A (en) Novel fused heterocycles and uses thereof
ATE442358T1 (de) Verbindungen und verfahren zur behandlung von dyslipidemie
BRPI0519292A2 (pt) compostos orgÂnicos
ATE432930T1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
ATE502631T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
SE0303090D0 (sv) Novel compounds
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
DE602004003829D1 (de) 2-ä4-(phenylamino)-piperidin-1-ylü-n-phenyl-acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit
ATE345795T1 (de) 1-phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivate und verwandte verbindungen als faktor xa inhibitoren zur behandlung von akuten gefässerkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Ref document number: 1735320

Country of ref document: EP

R082 Change of representative

Ref document number: 1735320

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE